98%
921
2 minutes
20
Introduction: Stroke, the second leading cause of death and disability in Europe, is primarily caused by interrupted blood supply, leading to ischemia-reperfusion (IR) injury and subsequent neuronal death. Current treatment options are limited, highlighting the need for novel therapies. Neural stem cells (NSCs) have shown promise in treating various neurological disorders, including stroke. However, the underlying mechanisms of NSC-mediated recovery remain unclear.
Methods: Eighty C57Bl/6-Tyrc-Brd mice underwent ischemic stroke induction and were divided into four groups: sham, stroke-affected, stroke-affected with basal cell medium injection, and stroke-affected with NSCs transplantation. NSCs, isolated from mouse embryos, were stereotaxically transplanted into the stroke-affected brains. Magnetic resonance imaging (MRI) and neurological scoring were used to assess recovery. Immunohistochemical analysis and gene expression assays were performed to evaluate pyroptosis and necroptosis markers.
Results: NSC transplantation significantly improved neurological recovery compared to control groups. In addition, although not statistically significant, NSCs reduced stroke volume. Immunohistochemical analysis revealed upregulation of Gasdermin D (GSDMD) expression post-stroke, predominantly in microglia and astrocytes. However, NSC transplantation led to a reduction in GSDMD signal intensity in astrocytes, suggesting an effect of NSCs on GSDMD activity. Furthermore, NSCs downregulated Mixed Lineage Kinase Domain-Like Protein () expression, indicating a reduction in necroptosis. Immunohistochemistry demonstrated decreased phosphorylated MLKL (pMLKL) signal intensity in neurons while stayed the same in astrocytes following NSC transplantation, along with increased distribution in microglia.
Discussion: NSC transplantation holds therapeutic potential in stroke recovery by targeting pyroptosis and necroptosis pathways. These findings shed light on the mechanisms underlying NSC-mediated neuroprotection and support their further exploration as a promising therapy for stroke patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358122 | PMC |
http://dx.doi.org/10.3389/fnmol.2024.1439994 | DOI Listing |
Drug Des Devel Ther
September 2025
Department of Neurosurgery, Peking University People's Hospital, Beijing, People's Republic of China.
Introduction: Parkinson's disease (PD) is a neurodegenerative disorder lacking therapies to replace lost dopaminergic neurons. Neural stem cell (NSC) transplantation faces survival and differentiation challenges. This study investigated feasibility and efficacy of paeoniflorin (PF) combined with NSC transplantation for PD treatment.
View Article and Find Full Text PDFAdv Sci (Weinh)
August 2025
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Cell transplantation offers a promising approach for treating Parkinson's disease (PD), but the limited survival of transplanted cells remains a major challenge. Reactive astrocytes, abundant in PD brains, may exacerbate this issue. GLP1R agonists, like semaglutide, are shown to inhibit reactive astrocytes in PD models.
View Article and Find Full Text PDFPharmacol Res
September 2025
Department of Neuroscience Rita Levi-Montalcini, University of Turin, Turin 10126, Italy; Neuroscience Institute Cavalieri Ottolenghi, University of Turin, Orbassano 10043, Italy. Electronic address:
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene. This leads to progressive loss of striatal neurons and motor-cognitive decline. While current gene-targeting approaches aiming at reducing somatic instability show promise - especially in case of early treatment - they cannot restore the already compromised neuronal circuitry at advanced disease stages.
View Article and Find Full Text PDF